Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label migalastat study in Fabry disease patients with severe renal impairment or end-stage renal disease on hemodialysis
2022-500488-10-00Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Dec 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of migalastat in Fabry disease (FD) (2 arms), sponsored by Amicus Therapeutics. Primary endpoint: Pharmacokinetic parameters and dosing confirmation. Started Dec 2022; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2022-500488-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500488-10-00.